CStone Pharmaceuticals (HKEX: 2616), a biopharmaceutical company, announced on Friday that it has named Shirley Zhao as its new general manager for Greater China and head of Commercial.

In the new role, Zhao will be responsible for the commercialisation of the company's products and will report directly to Dr Frank Jiang, chairman and CEO of CStone.

The company says that Zhao is a seasoned industry leader with more than 26 years of experience working at multiple multinational biopharmaceutical companies. She has effectively executed various critical initiatives. Before joining CStone, she was the Country GM for Bristol-Myers Squibb (BMS) China, where she successfully led the launch of Opdivo, the first anti-PD-1 antibody to enter the China market. She spearheaded the development of the rare disease, oncology, and medical aesthetics markets in China. Prior to BMS, she served as country GM at Genzyme and Allergan. Early in her career, she mainly concentrated in Oncology, including 10 years at Eli Lilly and five years at BMS. As a representative of the pharmaceutical industry, she made contributions to the formation and development of the Chinese Society of Clinical Oncology. In addition, she was also a co-founder and advocate of the China Lung Cancer Summit.